ReviewCancer management and research2014
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.
Review in Cancer management and research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review.Oncology research · 2016Pooled it
- Effects of the Foam Massage Roller on VEGF-A and FGF-2 Blood Levels in Young Men.In vivo (Athens, Greece)Trial
- Survival of a patient with glioblastoma multiforme after undergoing bone flap surgery followed by chemoradiotherapy to maintain tumor-treating fields: A case report.The Journal of international medical research · 2025Article
- 4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells.Scientific reports · 2023Article
- The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma.Biomedicines · 2022Review
- Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.Neuro-oncology practice · 2021Article
- Current FDA-Approved Therapies for High-Grade Malignant Gliomas.Biomedicines · 2021Review
- Anticancer Mechanism of Curcumin on Human Glioblastoma.Nutrients · 2021Review
- Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma.Cancer drug resistance (Alhambra, Calif.) · 2020Article
- Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
- Overexpression of HOXC6 promotes cell proliferation and migration via MAPK signaling and predicts a poor prognosis in glioblastoma.Cancer management and research · 2019Article
- LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression.Cancer management and research · 2019Article
- Glioblastoma Treatment Modalities besides Surgery.Journal of Cancer · 2019Review
- Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials.Cancer management and research · 2018Article
- Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- A comprehensive profile of recurrent glioblastoma.Oncogene · 2016Review
- Survival in glioblastoma: a review on the impact of treatment modalities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
- Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma.AJNR. American journal of neuroradiology · 2016Article
- Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.British journal of cancer · 2016Review
- Hallmarks of glioblastoma: a systematic review.ESMO open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) remains one of the most devastating tumors, and patients have a median survival of 15 months despite aggressive local and systemic therapy, including maximal surgical resection, radiation therapy, and concomitant and adjuvant temozolomide. The purpose of antineoplastic treatment is therefore to prolong life, with a maintenance or improvement of quality of life. GBM is a highly vascular tumor and overexpresses the vascular endothelial growth factor A, which promotes angiogenesis. Preclinical data have suggested that anti-angiogenic treatment efficiently inhibits tumor growth. Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor A, and treatment has shown impressive response rates in recurrent GBM. In addition, it has been shown that response is correlated to prolonged survival and improved quality of life. Several investigations in newly diagnosed GBM patients have been performed during recent years to test the hypothesis that newly diagnosed GBM patients should be treated with standard multimodality treatment, in combination with bevacizumab, in order to prolong life and maintain or improve quality of life. The results of these studies along with relevant preclinical data will be described, and pitfalls in clinical and paraclinical endpoints will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.